Humacyte Inc (HUMA)
4.94
-0.15
(-2.95%)
USD |
NASDAQ |
Jun 25, 16:00
4.94
0.00 (0.00%)
After-Hours: 20:00
Humacyte Research and Development Expense (Annual): 76.55M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 76.55M |
| December 31, 2022 | 63.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 61.34M |
| December 31, 2020 | 54.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
54.08M
Minimum
2020
76.55M
Maximum
2023
63.81M
Average
62.30M
Median
Research and Development Expense (Annual) Benchmarks
| Aquestive Therapeutics Inc | 13.10M |
| Revance Therapeutics Inc | 79.41M |
| AN2 Therapeutics Inc | 54.87M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |